First Horizon Advisors, Inc. Neurocrine Biosciences Inc Transaction History

First Horizon Advisors, Inc.

$3.81 Billion
Q2 2025

A detailed history of First Horizon Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 433 shares of NBIX stock, worth $62,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares

433

Previous 385 12.47%

Holding current value

$62,724

Previous $42,000 28.57%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 05, 2025	BUY	$87.54 - $128.18 $4,201 - $6,152	48 Added 12.47%	433 $54,000
Q1 2025 Apr 28, 2025	SELL	$107.22 - $153.29 $51,465 - $73,579	-480 Reduced 55.49%	385 $42,000
Q4 2024 Feb 03, 2025	SELL	$111.62 - $139.44 $15,850 - $19,800	-142 Reduced 14.1%	865 $118,000
Q3 2024 Nov 08, 2024	BUY	$114.58 - $153.15 $20,166 - $26,954	176 Added 21.18%	1,007 $115,000
Q2 2024 Jul 19, 2024	BUY	$130.86 - $143.19 $6,412 - $7,016	49 Added 6.27%	831 $114,000
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $7,849 - $9,824	74 Added 10.45%	782 $103,000
Q2 2023 Aug 03, 2023	SELL	$89.53 - $104.87 $984 - $1,153	-11 Reduced 1.53%	708 $66,000
Q4 2022 Feb 10, 2023	BUY	$106.72 - $127.06 $6,936 - $8,258	65 Added 9.94%	719 $85,000
Q3 2022 Nov 09, 2022	SELL	$92.03 - $107.81 $4,141 - $4,851	-45 Reduced 6.44%	654 $69,000
Q2 2022 Aug 02, 2022	BUY	$75.79 - $100.07 $14,475 - $19,113	191 Added 37.6%	699 $68,000
Q1 2022 May 10, 2022	SELL	$72.45 - $94.81 $30,501 - $39,915	-421 Reduced 45.32%	508 $48,000
Q4 2021 Feb 09, 2022	SELL	$79.65 - $106.22 $8,203 - $10,940	-103 Reduced 9.98%	929 $79,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $12,496 - $14,359	-145 Reduced 12.32%	1,032 $98,000
Q3 2021 Nov 09, 2021	BUY	$86.18 - $99.03 $38,694 - $44,464	449 Added 61.68%	1,177 $112,000
Q2 2021 Aug 09, 2021	BUY	$89.43 - $102.27 $4,292 - $4,908	48 Added 7.06%	728 $70,000
Q1 2021 May 11, 2021	BUY	$87.57 - $119.4 $1,050 - $1,432	12 Added 1.8%	680 $66,000
Q4 2020 Feb 11, 2021	BUY	$86.91 - $108.33 $21,292 - $26,540	245 Added 57.92%	668 $64,000
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $23,847 - $33,517	248 Added 141.71%	423 $40,000
Q1 2020 May 05, 2020	BUY	$75.11 - $113.76 $2,854 - $4,322	38 Added 27.74%	175 $15,000
Q3 2019 Oct 23, 2019	SELL	$83.82 - $101.5 $586 - $710	-7 Reduced 4.86%	137 $12,000
Q1 2019 Apr 26, 2019	BUY	$69.31 - $91.53 $9,980 - $13,180	144 New	144 $0

Others Institutions Holding NBIX

# of Institutions

724

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.

Account

First Horizon Advisors, Inc. Neurocrine Biosciences Inc Transaction History